Table of contents
- Gerresheimer share 2025: Between crisis and opportunity
- Gerresheimer share analysis in 120 seconds
- What does Gerresheimer do
- Analysis of business figures
- Explanation of possible risks or price declines
- Analyst opinions
- Valuation and price development
- Conclusion with recommendation
- Try TransparentShare free for 14 days
- Download links for the app
- Investor Relations
Gerresheimer share 2025: Between crisis and opportunity
Gerresheimer shares are in the spotlight of many investors. A profit warning, a lowered forecast, and an ongoing BaFin audit are creating uncertainty. At the same time, the group is working on a radical restructuring toward high-margin pharmaceutical solutions. This article provides a clear overview of the key figures, opportunities, and risks, as well as the current valuation in the TransparentShare app. This will help you decide more quickly whether monitoring or an initial investment is better suited to your strategy.
Gerresheimer share analysis in 120 seconds
If you want the most important facts explained in a concise and understandable way, then watch our short YouTube video now. In it, we clearly summarize the key figures, risks, and valuation.
What does Gerresheimer do
Düsseldorf-based Gerresheimer is a leading provider of packaging and systems for pharmaceuticals and healthcare. Its portfolio ranges from vials and syringes to insulin pens and inhalers to specialized solutions for biotech applications. Customers include international pharmaceutical corporations and biotech companies that demand the highest quality standards. Cosmetics packaging accounts for a smaller share of revenue. The company's strategic focus is on complex pharmaceutical systems with higher added value. Less profitable areas will be gradually reduced or divested.
Analysis of business figures
On October 9, 2025, Gerresheimer lowered its annual targets. Instead of slight growth, management now expects an organic decline in revenue of 2 to 4 percent. The adjusted EBITDA margin is expected to be between 18.5 and 19 percent. Earnings per share will also decline more sharply than previously expected. This is due to weaker demand in the cosmetics business and fewer orders for packaging for liquid medications. Preliminary revenues of €560.7 million and adjusted EBITDA of €103.4 million were reported for the third quarter. The organic decline was approximately 1.2 percent. At the same time, a transformation program with cost reductions and efficiency measures was launched. Free cash flow was positive, which is a stability factor in the current situation.
Explanation of possible risks or price declines
The increasing number of profit warnings is weighing on confidence. Following the latest announcement, the share price fell significantly at times and is trading well below its annual high. The BaFin audit is creating further uncertainty. The investigation is investigating whether revenues were booked prematurely. Gerresheimer emphasizes that it has correctly prepared its financial statements and points to a low double-digit million amount as the scope of the disputed issue. Further risks include a possible delay in the group's restructuring, economic conditions and demand in the pharmaceutical sector, energy costs, and exchange rate effects. Opportunities arise from the strategic focus on high-margin pharmaceutical systems, new customer projects, and a potential recovery after the audit is completed.
Analyst opinions
Assessments are divided. Some analysts see increased risks and advise caution or selling. Others remain constructive and point to the long-term opportunities offered by the repositioning. Thus, alongside downgrades, there are also buy recommendations in the market. For example, price targets are mentioned, some of which are significantly higher than the current price, while cautious firms set lower targets. For investors, this means closely monitoring upcoming milestones such as strategic updates and progress in the restructuring.
Valuation and price development
In the TransparentShare app, Gerresheimer shares are currently rated +1 point for 2025. Rating as of October 8, 2025. We view the expected earnings growth for next year and a favorable price-to-book ratio as positive factors. The weak share price performance of the past few months and the recently reduced margin are negative factors. The share price remains well below its 52-week high, which opens up opportunities in the event of a successful turnaround, but also represents increased risk.
Conclusion with recommendation
Gerresheimer is undergoing a challenging transition phase. The combination of a lowered forecast, BaFin audit, and transformation explains the high level of uncertainty. At the same time, the focus on high-margin pharmaceutical solutions opens up the opportunity for more stable margins and profitable growth. For conservative investors, the recommendation is to monitor and look for clear signals from the strategy update, order intake, and margins. Our current assessment in the TransparentShare app remains "monitor."
Try TransparentShare free for 14 days
Make your investment decisions based on data, not gut feeling. TransparentShare shows you daily which stocks are worth buying and which ones you should avoid. Use clear valuations, objective metrics, and understandable analyses for better decisions.
Register now and test for 14 days
Download links for the app
👉 TransparentShare in the Apple App Store
👉 TransparentShare on the Google Play Store
Investor Relations
Further in-depth information can be found on Gerresheimer’s official Investor Relations page.
👉 To the Investor Relations page
Note: All information is provided without guarantee. This article does not constitute investment advice and is not a substitute for individual advice.
